
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Oncolology, Markers, Clinical Correlates |
Johannes Gutenberg-University, 3rd Department of Internal Medicine, D-55101 Mainz, Germany [B. S., M. B., U. R., C. H.]; University Witten/Herdecke, Institute of Pathology, 42283 Wuppertal, Germany [D. A., S. S.]; and Roswell Park Cancer Institute, Department of Immunology, Buffalo, New York [S. F.]
The HLA class I antigen-processing machinery (APM) plays a crucial role in the generation of peptides from endogenously synthesized proteins and in their presentation to cytotoxic T lymphocytes. The potential role of defects of APM components in immune escape mechanisms used by malignant cells has prompted us to analyze their expression in renal cell carcinoma (RCC) lesions with special emphasis on TAP because of its critical role in the loading of HLA class I antigens with peptides. Immunohistochemical staining of 51 formalin-fixed RCC lesions and autologous normal renal epithelium detected transporter associated with antigen processing (TAP)1 and tapasin deficiencies in 63 and 80% of the tumor lesions. Impaired low molecular weight protein (LMP)2 and LMP7 expression was found in 73 and 33% of the RCC lesions analyzed, respectively. In contrast to the high frequency of APM component down-regulation, HLA class I heavy chain and ß2-microglobulin defects were detected in only 12 and 10% of the lesions, respectively. Concomitant TAP1 and LMP2 deficiencies were found in
57% of RCC lesions, whereas a coordinated down-regulation of all APM components occurred only in 5% of the tumor specimens analyzed. The presence of APM defects was independent of tumor stage and grade but varied significantly among the RCC subtypes. TAP abnormalities do not appear to be attributable to structural alterations because no mutations in TAP1 were detected in TAP1-deficient RCC lesions. These data suggest that TAP defects in RCC lesions are caused by regulatory abnormalities. Therefore, T-cell-based immunotherapy may benefit from the administration of cytokines that up-regulate TAP expression.
This article has been cited by other articles:
![]() |
I. Pellicciotta, X. Cortez-Gonzalez, R. Sasik, Y. Reiter, G. Hardiman, P. Langlade-Demoyen, and M. Zanetti Presentation of Telomerase Reverse Transcriptase, a Self-Tumor Antigen, is Down-regulated by Histone Deacetylase Inhibition Cancer Res., October 1, 2008; 68(19): 8085 - 8093. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Y. Han, M. S. Fletcher, D. L. Urbauer, P. Mueller, C. N. Landen, A. A. Kamat, Y. G. Lin, W. M. Merritt, W. A. Spannuth, M. T. Deavers, et al. HLA Class I Antigen Processing Machinery Component Expression and Intratumoral T-Cell Infiltrate as Independent Prognostic Markers in Ovarian Carcinoma Clin. Cancer Res., June 1, 2008; 14(11): 3372 - 3379. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Ogino, H. Shigyo, H. Ishii, A. Katayama, N. Miyokawa, Y. Harabuchi, and S. Ferrone HLA Class I Antigen Down-regulation in Primary Laryngeal Squamous Cell Carcinoma Lesions as a Poor Prognostic Marker. Cancer Res., September 15, 2006; 66(18): 9281 - 9289. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Norell, M. Carlsten, T. Ohlum, K.-J. Malmberg, G. Masucci, K. Schedvins, W. Altermann, D. Handke, D. Atkins, B. Seliger, et al. Frequent Loss of HLA-A2 Expression in Metastasizing Ovarian Carcinomas Associated with Genomic Haplotype Loss and HLA-A2-Restricted HER-2/neu-Specific Immunity. Cancer Res., June 15, 2006; 66(12): 6387 - 6394. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Facoetti, R. Nano, P. Zelini, P. Morbini, E. Benericetti, M. Ceroni, M. Campoli, and S. Ferrone Human Leukocyte Antigen and Antigen Processing Machinery Component Defects in Astrocytic Tumors Clin. Cancer Res., December 1, 2005; 11(23): 8304 - 8311. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Lou, T. Z. Vitalis, G. Basha, B. Cai, S. S. Chen, K. B. Choi, A. P. Jeffries, W. M. Elliott, D. Atkins, B. Seliger, et al. Restoration of the Expression of Transporters Associated with Antigen Processing in Lung Carcinoma Increases Tumor-Specific Immune Responses and Survival Cancer Res., September 1, 2005; 65(17): 7926 - 7933. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. F. Setiadi, M. D. David, S. S. Chen, J. Hiscott, and W. A. Jefferies Identification of Mechanisms Underlying Transporter Associated with Antigen Processing Deficiency in Metastatic Murine Carcinomas Cancer Res., August 15, 2005; 65(16): 7485 - 7492. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Kloor, C. Becker, A. Benner, S. M. Woerner, J. Gebert, S. Ferrone, and M. von Knebel Doeberitz Immunoselective Pressure and Human Leukocyte Antigen Class I Antigen Machinery Defects in Microsatellite Unstable Colorectal Cancers Cancer Res., July 15, 2005; 65(14): 6418 - 6424. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |